3 research outputs found
Summary of the characteristics, expression, the availability of mouse model, and association to cancers of B- and Y-family translesion synthesis polymerases.
<p>Summary of the characteristics, expression, the availability of mouse model, and association to cancers of B- and Y-family translesion synthesis polymerases.</p
DNA damage bypass process.
<p>(A) Mechanism of the 2-step DNA damage bypass process. To bypass DNA damage, REV1 inserts deoxycytidine triphosphates across the damage or orchestrates the recruitment of the other polymerases, POL ι, POL κ, POL η, to replicate across the damage. Thereafter, POL ζ complex can help extend beyond the damage to enable re-initiation of undamaged DNA replication. If an incorrect nucleotide gets incorporated across the damage, this misincorporated nucleotide will lead to a mutation in the next round of replication. (B) A schematic representing the protein domains of the Y-family translesion synthesis (TLS) polymerases, REV1, POL ι, POL κ, POL η.</p
Identification of Small Molecule Translesion Synthesis Inhibitors That Target the Rev1-CT/RIR Protein−Protein Interaction
Translesion synthesis
(TLS) is an important mechanism through which
proliferating cells tolerate DNA damage during replication. The mutagenic
Rev1/Polζ-dependent branch of TLS helps cancer cells survive
first-line genotoxic chemotherapy and introduces mutations that can
contribute to the acquired resistance so often observed with standard
anticancer regimens. As such, inhibition of Rev1/Polζ-dependent
TLS has recently emerged as a strategy to enhance the efficacy of
first-line chemotherapy and reduce the acquisition of chemoresistance
by decreasing tumor mutation rate. The TLS DNA polymerase Rev1 serves
as an integral scaffolding protein that mediates the assembly of the
active multiprotein TLS complexes. Protein–protein interactions
(PPIs) between the C-terminal domain of Rev1 (Rev1-CT) and the Rev1-interacting
region (RIR) of other TLS DNA polymerases play an essential role in
regulating TLS activity. To probe whether disrupting the Rev1-CT/RIR
PPI is a valid approach for developing a new class of targeted anticancer
agents, we designed a fluorescence polarization-based assay that was
utilized in a pilot screen for small molecule inhibitors of this PPI.
Two small molecule scaffolds that disrupt this interaction were identified,
and secondary validation assays confirmed that compound <b>5</b> binds to Rev1-CT at the RIR interface. Finally, survival and mutagenesis
assays in mouse embryonic fibroblasts and human fibrosarcoma HT1080
cells treated with cisplatin and ultraviolet light indicate that these
compounds inhibit mutagenic Rev1/Polζ-dependent TLS in cells,
validating the Rev1-CT/RIR PPI for future anticancer drug discovery
and identifying the first small molecule inhibitors of TLS that target
Rev1-CT